<DOC>
	<DOCNO>NCT01244750</DOCNO>
	<brief_summary>The purpose study well understand use tyrosine kinase inhibitor ( TKI ) patient newly diagnose CML quality life real-world setting .</brief_summary>
	<brief_title>Studying First Line Treatment Chronic Myeloid Leukemia ( CML ) Real-world Setting</brief_title>
	<detailed_description>Time Perspective : Most patient expect mix retrospective prospective data collection . Patients enrol study index date ( retrospective component ) follow 5 year study index date complete ( time enrollment 5 year follow-up prospective component )</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Newlydiagnosed chronic phase chronic myeloid leukemia ( CPCML ) patient start firstline Tyrosine Kinase Inhibitor ( TKI ) treatment imatinib , dasatinib nilotinib accordance timeline 18 year old time CPCML diagnosis ) Imatinib Cohorts Patients start firstline Imatinib treatment January 2 , 2008 September 30 , 2010.Patients fit criterion define retrospective Imatinib patient âˆ’ Patients start firstline Imatinib treatment October 1 , 2010 b ) Dasatinib Cohort Patients start firstline Dasatinib treatment drug approve indication c ) Nilotinib Cohort Patients start firstline Nilotinib treatment drug approve indication Patients also eligible already switch subsequent therapy ( TKI ) time enrollment , long firstline subsequent CML treatment information available site data entry study Electronic Case Report Form ( eCRF ) Receiving treatment medical practice ( eg . communitybased , officebased , hospitalbased , academic setting , oncology center ) Patients participate interventional trial may influence management CML disease exclude Discontinuation Criteria : Enrolled patient join interventional trial may influence management CML disease exclude time entry interventional trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Chronic Phase - Chronic Myeloid Leukemia</keyword>
</DOC>